Blog

His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? – Xconomy


Xconomy

His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision?
Xconomy
Perhaps this year, Spark Therapeutics could be the first ever in the U.S. to win approval of a gene therapy with its one-time treatment for an inherited form of blindness. But an approval could also throw Spark into the line of fire in the U.S. fight

2017-02-16 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.